Recursion Pharmaceuticals shares surged 16% pre-market after the company beat Wall Street expectations with Q4 revenue of $35.5 million. CEO Najat Khan stated the company reached an inflection point, moving beyond proving AI in discovery to demonstrating clinical proof and durable value for its AI-native operating system.